



# Menopause:

---

## Navigating Nutrition in Midlife

PRESENTED BY  
Whitney Crowe, MD, MSCP




I HAVE NO CONFLICTS OF INTEREST TO  
DISCLOSE

# OBJECTIVES

1. DESCRIBE THE PHYSIOLOGICAL CHANGES THAT OCCUR DURING MENOPAUSE.
2. NAME COMMON SYMPTOMS WOMEN EXPERIENCE DURING THE MENOPAUSAL TRANSITION, INCLUDING THE HEALTH RISKS THAT ARE ASSOCIATED.
3. RECOGNIZE THE NUTRITIONAL NEEDS OF A MIDLIFE WOMAN.

# PHYSIOLOGY: THE BASICS



**FIGURE 33.1.** The reproductive cycle requires complex interactions and feedback between the hypothalamus, pituitary, and ovaries which are simplified in this diagram. CNS = central nervous system; GnRH = gonadotropin-releasing hormone; FSH = follicle stimulating hormone; LH = luteinizing hormone.

- FEMALES ARE BORN WITH ALL THE OOCYTES THEY WILL EVER HAVE WHICH IS APPROXIMATELY ONE MILLION FOLLICLES
- FOLLICULAR LOSS OCCURS BEFORE A FEMALE IS EVEN BORN
- AS FOLLICULAR NUMBER DECREASES, THERE IS REDUCED INHIBIN-B RELEASE □ UPREGULATION IN FSH SECRETION FROM THE PITUITARY □ INCREASED E2 PRODUCTION FROM THE OVARIES... UNTIL THE OVARIES “BURN OUT” = MENOPAUSE

# TERMINOLOGY

- EARLY MENOPAUSE AND LATE MENOPAUSE
  - USED TO DESCRIBE MENOPAUSE THAT OCCURS EARLIER OR LATER THAN WITHIN THE NORMAL RANGE OF AGES (FMP BEFORE 45 OR FMP AFTER 54)
- EARLY POST-MENOPAUSE AND LATE POST-MENOPAUSE
  - EARLY IF THEY ARE WITHIN 8 YEARS OF THEIR FMP, OTHERWISE LATE
- MENOPAUSE TRANSITION
  - TIME BEFORE THE FMP WHEN THE MENSTRUAL CYCLE BECOMES VARIABLE OR OTHER MENOPAUSE-RELATED SYMPTOMS BEGIN
- PERIMENOPAUSE – “AROUND MENOPAUSE”
  - ONSET OF INTERMENSTRUAL CYCLE IRREGULARITIES OR OTHER MENOPAUSE-RELATED SYMPTOMS AND EXTENDS BEYOND THE FMP TO INCLUDE THE 12 MONTHS AFTER MENOPAUSE
  - ENCOMPASSES 1 YEAR LONGER THAN MENOPAUSE TRANSITION

Executive summary  
of the Stages of  
Reproductive Aging  
Workshop + 10:  
addressing the  
unfinished agenda of  
staging reproductive  
aging

**Figure 1.** The Stages of Reproductive Aging Workshop + 10 Staging System

	Menarche				FMP (0)					
Stage	-5	-4	-3b	-3a	-2	-1	+1a	+1b	+1c	+2
Terminology	REPRODUCTIVE				MENOPAUSE TRANSITION		POSTMENOPAUSE			
	Early	Peak	Late		Early	Late	Early		Late	
					Perimenopause					
Duration	variable				variable	1-3	2 (1+1)		3-6	Remaining lifespan
PRINCIPAL CRITERIA										
Menstrual cycle	Variable to regular	Regular	Regular	Subtle changes in flow/ length	Variable length Persistent ≥7-day difference in length of consecutive cycles	Interval of amenorrhea of ≥60 days				
SUPPORTIVE CRITERIA										
Endocrine FSH AMH Inhibin B			Low Low	Variable <sup>a</sup> Low Low	↑ Variable <sup>a</sup> Low Low	↑ >25IU/L <sup>b</sup> Low Low	↑ Variable <sup>a</sup> Low Low	Stabilizes Very low Very low		
Antral follicle count			Low	Low	Low	Low	Very low	Very low		
DESCRIPTIVE CHARACTERISTICS										
Symptoms						Vasomotor symptoms Likely	Vasomotor symptoms Most likely			Increasing symptoms of urogenital atrophy

↑ indicates elevated.

a. Blood draw on cycle days 2-5.

b. Approximate expected level based on assays using current international pituitary standard.

Abbreviations: AMH, antimüllerian hormone; FMP, final menstrual period; FSH, follicle-stimulating hormone.

Adapted from Harlow SD, et al.<sup>9</sup> © North American Menopause Society.



# WHY SHOULD YOU CARE?

- BY 2031, ABOUT 1.2 BILLION WOMEN GLOBALLY WILL HAVE REACHED MENOPAUSE
- ASSOCIATED WITH ELEVATED CARDIOVASCULAR RISK
- UNTREATED SYMPTOMS HAVE BEEN ASSOCIATED WITH HIGHER HEALTHCARE COSTS, NEGATIVE EFFECTS ON QUALITY OF LIFE, AND ADVERSE EFFECTS FOR WOMEN IN THE WORKPLACE
- WE TALK TO TEENAGERS ABOUT PUBERTY BUT RARELY MENTION MENOPAUSE TO MIDDLE-AGED WOMEN

# COMMON SYMPTOMS

- VASOMOTOR SYMPTOMS
- GENITOURINARY SYMPTOMS
- MOOD DISTURBANCES
- COGNITIVE CHANGES
- SKIN AND HAIR CHANGES
- DIFFICULTY SLEEPING
- CHANGES IN LIBIDO
- HEADACHES
- WEIGHT GAIN
- ARTHRALGIAS

\*not all symptoms are related to hormone changes; some are age related



# VASOMOTOR SYMPTOMS

- AKA – HOT FLASHES, HOT FLUSHES, AND NIGHT SWEATS
  - “THE HALLMARK OF MENOPAUSE”
- TRANSIENT SENSATION OF HEAT, FLUSHING, AND SWEATING
- SOME MAY DESCRIBE THIS AS “SEVERE ANXIETY” OR “PANIC ATTACKS”
- 80% OF WOMEN WITH MEDIAN DURATION OF 7.4 YEARS
- THESE LEAD TO OTHER ISSUES — SLEEP, MOOD, CARDIOVASCULAR, BONE
- NOT ALL VMS SYMPTOMS ARE HORMONE RELATED

# GENITOURINARY SYNDROME OF MENOPAUSE

- VAGINAL DRYNESS
- PRURITUS
- BURNING
- DYSPAREUNIA
- URINARY URGENCY
- FREQUENT URINARY TRACT INFECTIONS
- AFFECTS MORE THAN 50% OF WOMEN DURING THE MENOPAUSAL TRANSITION AND 27-84% OF WOMEN EXPERIENCE ISSUES POSTMENOPAUSAL

# BODY CHANGES

- “I JUST DON’T FEEL LIKE MYSELF”
- WEIGHT GAIN — AVERAGE OF 5-7 POUNDS
- CHANGE IN BODY WEIGHT COMPOSITION — FROM PEAR TO APPLE
- CHANGE IN BASAL METABOLIC RATE OF UP TO 250–300 KCAL PER DAY

## 'EARLY' PERIMENOPAUSE



### Hormones\*

↔ E<sub>2</sub> (relatively unchanged)

↑ FSH \*

### CVD Risk Factors

↑ C-IMT and vascular remodeling

↓ Endothelial function (FMD)

**NOTE:** Few studies of women in early perimenopause have been conducted due to the inherent difficulty in categorizing women in this earlier stage. As a result, the cardiometabolic changes that occur during early perimenopause have yet to be fully elucidated.

## 'LATE' PERIMENOPAUSE



### Hormones\*

↓ E<sub>2</sub> \* and AMH

↑ FSH \*

### Body Composition

↑ Fat mass (abdominal fat)

↓ Fat-free (lean) mass

### Energy Intake & Expenditure



↓ 24-h, Sleep, & Physical Activity EE

Resting EE (?)

Fat oxidation

Energy Intake

### Cardiovascular Risk Factors



↑ Dyslipidemia (mostly within 1-year of FMP)

↑ C-IMT, Aortic PWV, and vascular remodeling

↓ Endothelial function (FMD) and cardiac health

↑ Insulin resistance

↑ Sleep disturbances

## POSTMENOPAUSE

### Hormones\*

↓ E<sub>2</sub> (for 2 years after FMP, then stabilizes) \*

↑ FSH (for 2 years after FMP, then stabilizes) \*

### Body Composition

↑ Fat mass (abdominal fat) (for 2 years after FMP, then stabilizes)

↓ Fat-free (lean) mass (for 2 years after FMP, then stabilizes)

### Energy Intake & Expenditure

↓ 24-h and Sleep EE

Physical Activity EE

Fat oxidation

(remains low into postmenopausal years)

### Cardiovascular Risk Factors

↑ Dyslipidemia (mostly within 1-year of FMP)

↑ Insulin resistance and glucose intolerance (associated with abdominal fat accumulation)

↑ Sleep disturbances



# INSULIN SENSITIVITY AND GLUCOSE TOLERANCE

- MIXED EVIDENCE ON ASSOCIATION BETWEEN MENOPAUSE AND DIABETES
- MULTIPLE STUDIES HAVE SHOWN NO ASSOCIATION BETWEEN NATURAL MENOPAUSE AND DIABETES<sup>6,7,8</sup>
- SWAN STUDY DID SHOW INCREASE IN METABOLIC SYNDROME 2/2 TO LIPIDS
- SEVERAL STUDIES HAVE ALSO SHOWN THAT HORMONE THERAPY REDUCES THE RISK OF DEVELOPING DMII<sup>11-13</sup>
- NOT AS CLEAR AS WE WOULD LIKE FOR IT TO BE
- WHAT WE DO KNOW:
  - ESTROGEN □ PERIPHERAL FAT DISTRIBUTION, IMPROVES INSULIN SENSITIVITY<sup>9</sup>
  - INCREASED BMI, AS WELL AS INCREASED ABDOMINAL ADIPOSITY, ARE STRONGLY LINKED TO INSULIN RESISTANCE, DMII, AND CVD<sup>10</sup>

# DYSLIPIDEMIA

- “FROM PEAR TO APPLE” — INCREASE IN ABDOMINAL FAT LEADS TO CHANGES IN LIPIDS
- FEMALE HORMONES, PRIMARILY ESTROGEN, MAY BE PROTECTIVE AGAINST DYSLIPIDEMIA
- SWAN STUDY: DRASTIC INCREASE IN TOTAL CHOLESTEROL, LDL-C, AND APOLIPOPROTEIN B WITHIN 1 YEAR INTERVAL SURROUNDING FMP.<sup>14</sup>
- ELEVATIONS IN LDL-C AND TRIGLYCERIDES LEADS TO GREATER RISK OF CAROTID PLAQUE AND THE ATHEROSCLEROTIC PROCESS

# SLEEP DISRUPTIONS

- SWAN: MORE SLEEP DISTURBANCES AS THEY PROGRESS THROUGH THE MENOPAUSAL STAGES
  - INCREASES FROM 16-42% PREMENOPAUSE, TO 39-47% IN PERIMENOPAUSE AND 35-60% IN POSTMENOPAUSE <sup>15</sup>
- INDEPENDENT OF VASOMOTOR SYMPTOMS
- SLEEP DISTURBANCE □ CHANGES IN HUNGER AND APPETITE □ METABOLIC ABNORMALITIES
- THEREFORE, WOMEN WHO EXPERIENCE WORSE SLEEP DISRUPTIONS MAY EXPERIENCE MORE WEIGHT GAIN AND ABDOMINAL FAT


# CARDIOVASCULAR DISEASE

- LEADING CAUSE OF MORTALITY IN POSTMENOPAUSAL WOMEN
- THE LOSS OF ESTROGEN LIKELY INCREASES THE RISK OF CVD
- RISK FACTORS INCLUDE VASCULAR DYSFUNCTION, HYPERTENSION, AND CARDIAC DYSFUNCTION



# VASCULAR DYSFUNCTION<sup>3</sup>

- AS PEOPLE AGE, THERE IS INCREASED OXIDATIVE STRESS AND INFLAMMATION LEADING TO REDUCED NITRIC OXIDE
- NITRIC OXIDE SYNTHASE IS ALSO IMPAIRED FURTHER REDUCING NO BIOAVAILABILITY
- ENDOTHELIAL DYSFUNCTION AND ARTERIAL STIFFENING
- VASCULAR FUNCTION APPEARS TO BE PRESERVED UNTIL MENOPAUSE WHEN ESTROGEN IS LOSS



Preservation of Vascular Endothelial Function in Late-Onset Postmenopausal Women




# HYPERTENSION

- INCIDENCE INCREASES WITH AGE
- BUT THE AGE-RELATED INCREASES ARE MORE RAPID IN WOMEN AND CORRELATED WITH MENOPAUSE
- MULTIFACTORIAL — WEIGHT GAIN, METABOLIC SYNDROME, ENDOTHELIAL DYSFUNCTION, ARTERIAL STIFFNESS

# CARDIAC DYSFUNCTION<sup>3</sup>



- THE PREVIOUSLY MENTIONED CHANGES CAN LEAD TO STRESS ON THE HEART
- MAJORITY CAUSED BY OVERALL INCREASE IN AFTERLOAD AND WORK NEEDED TO PERFORM BY THE LEFT VENTRICLE □ DIASTOLIC DYSFUNCTION □ HFpEF




<https://cards.rxexplained.com/2021/11/12/preload-and-afterload/>

# OSTEOPOROSIS<sup>1</sup>



- IMPAIRED BONE STRENGTH THAT INCREASES RISK OF FRACTURE
- BONE REMODELING
- IN PREMENOPAUSAL WOMEN, THIS IS BALANCED
- DURING MENOPAUSE, ESTROGEN DEFICIENCY LEADS TO RAPID BONE RESORPTION AND THE PROCESS IS NO LONGER BALANCED □ BONE LOSS AND GRADUAL BUT PROGRESSIVE DETERIORATION OF THE BONE ARCHITECTURE
- RISK FACTORS, CONSEQUENCES, TREATMENT/PREVENTION



<https://www.osteoporosis.foundation/health-professionals/about-osteoporosis/bone-biology>

# SO HOW CAN WE HELP?

- LIFESTYLE INTERVENTIONS
  - DIET
  - EXERCISE
  - THE EARLIER, THE BETTER
- MEDICATION

# PROTEIN

- 1-1.2 G/KG OF BODY WEIGHT
  - NEEDS TO BE COMBINED WITH REGULAR EXERCISE
- ESSENTIAL FOR INCREASING AND MAINTAINING SKELETAL MUSCLE

# CARBOHYDRATES

- 120g
- CHOICES SHOULD BE RICH IN VEGETABLE FIBERS, VITAMIN, AND MINERALS
- ADDED SUGAR INTAKE SHOULD BE NO MORE THAN 10% OF THE DAILY ENERGY INTAKE
- LOW GLYCEMIC INDEX, FIBER RICH = PROTECTIVE HEALTH EFFECTS
  - DECREASES RISK OF CVD, INTESTINAL MALIGNANCIES, AND DMII
- FIBER IS KING (ACTUALLY, QUEEN)
  - SATIATING
  - CHANGES INTESTINAL FLORA □ DECREASES RISK OF METABOLIC SYNDROME
  - MAY EVEN EFFECT ESTROGEN METABOLISM, SLOWING THE DEVELOPMENT OF SYMPTOMS FROM ESTROGEN DEFICIENCY

# FAT


- QUALITY OF FATTY ACIDS IN THE DIET > TOTAL AMOUNT
- REPLACE SATURATED FATTY ACIDS WITH POLYUNSATURATED FATTY ACIDS
- EMPHASIZE THE IMPORTANCE OF DIETARY INTAKE OF OMEGA-3 FATTY ACIDS



# VITAMIN D



- FAT SOLUBLE VITAMIN FOUND IN EGG YOLKS, DAIRY PRODUCTS, OILY FISH
- ESSENTIAL FOR ABSORPTION OF CALCIUM; THEREFORE, ESSENTIAL FOR BONE HEALTH
- OSTEOPOROSIS TREATMENT IS ONLY EFFECTIVE WITH ADEQUATE VITAMIN D (WITH OR WITHOUT SUPPLEMENTATION)
- RECOMMENDED DIETARY ALLOWANCE — 600 IU UNTIL 70 YEARS OLD THEN 800 IU



Spyksma, Eva & Alexandridou, Anastasia & Mai, Knut & Volmer, Dietrich & Stokes, Caroline. (2024). An Overview of Different Vitamin D Compounds in the Setting of Adiposity. *Nutrients*. 16. 231. 10.3390/nu16020231.

# CALCIUM

- MOST ABUNDANT MINERAL IN THE HUMAN BODY
- NEEDS CHANGE THROUGHOUT A WOMAN'S LIFE
  - INCREASE DURING TEEN YEARS, FALL DURING REPRODUCTIVE YEARS, AND RISE AGAIN AROUND MENOPAUSE (DECREASED INTESTINAL ABSORPTION, VITAMIN D DEFICIENCY)
- MOST CALCIUM REQUIREMENTS CAN BE MET WITH DIET ALONE
- DAIRY PRODUCTS, FOOD SUPPLEMENTED WITH CALCIUM
- RECOMMENDED DIETARY ALLOWANCE OF 1200 MG/D


# VITAMIN C

- NECESSARY FOR COLLAGEN FORMATION AND TISSUE REPAIR
- ALSO PLAYS IMPORTANT ROLE IN METABOLISM, IMMUNE FUNCTION, AND PRESERVATION OF VESSEL INTEGRITY
- SUPPLEMENTATION OFTEN NOT NECESSARY
- RECOMMENDED DIETARY ALLOWANCE IS 75 MG
- FRUITS AND VEGETABLES
  - PEPPERS
  - CITRUS FRUITS
  - SAUERKRAUT

# B VITAMINS



- THIAMIN, RIBOFLAVIN, NIACIN, PANTOTHENIC ACID, PYRIDOXINE, FOLIC ACID, AND CYANCOBALAMIN
- COFACTORS FOR ENZYMES THAT PLAY A HUGE ROLE IN THE METABOLISM OF CARBOHYDRATES, FATS, AND PROTEINS
- ALSO IMPORTANT FOR A REGULAR FUNCTIONING NERVOUS SYSTEM
- B VITAMINS CAN LOWER HOMOCYSTEINE LEVELS, REDUCING THE RISK OF STROKE AS WELL AS OSTEOPOROSIS AND RISK OF BONE FRACTURES



Godoy Parejo, Carlos & Deng, Chunhao & Zhang, Yumeng & Liu, Weiwei & Chen, Guokai. (2020). Roles of vitamins in stem cells. Cellular and Molecular Life Sciences. 77. 10.1007/s00018-019-03352-6.

# EXERCISE

- MULTIPLE BENEFITS
  - SLEEP, MOOD, CHRONIC DISEASE, BONE HEALTH
- DIET + EXERCISE = GREATEST WEIGHT AND FAT MASS LOSS
- AT LEAST 150 MIN/WK
- AEROBIC + RESISTANCE TRAINING

# RESOURCES

- THE MENOPAUSE SOCIETY -  
[HTTPS://MENOPAUSE.ORG/](https://menopause.org/)
- DR. JEN GUNTER
- DR. MARY CLAIRE HAVER
- HOW TO BALANCE YOUR HORMONES: WHAT YOUR DOCTOR ISN'T TELLING YOU ABOUT MENOPAUSE - THE MEL ROBBINS PODCAST WITH DR. JEN GUNTER MD



# REFERENCES

- 1. MENOPAUSE PRACTICE: A CLINICIAN'S GUIDE 6TH EDITION
- 2. KO SH, JUNG Y. ENERGY METABOLISM CHANGES AND DYSREGULATED LIPID METABOLISM IN POSTMENOPAUSAL WOMEN. *NUTRIENTS*. 2021 DEC 20;13(12):4556. DOI: 10.3390/nu13124556. PMID: 34960109; PMCID: PMC8704126.
- 3. MARLATT KL, PITYSKI-MILLER DR, GAVIN KM, ET AL. BODY COMPOSITION AND CARDIOMETABOLIC HEALTH ACROSS THE MENOPAUSE TRANSITION. *OBESITY (SILVER SPRING)*. 2022; 30: 14–27. [HTTPS://DOI.ORG/10.1002/OBY.23289](https://doi.org/10.1002/oby.23289)
- 4. ERDÉLYI A, PÁLFI E, TÚÚ L, NAS K, SZÚCS Z, TÖRÖK M, JAKAB A, VÁRBÍRÓ S. THE IMPORTANCE OF NUTRITION IN MENOPAUSE AND PERIMENOPAUSE-A REVIEW. *NUTRIENTS*. 2023 DEC 21;16(1):27. DOI: 10.3390/nu16010027. PMID: 38201856; PMCID: PMC10780928.
- 5. MILART P, WOŹNIAKOWSKA E, WRONA W. SELECTED VITAMINS AND QUALITY OF LIFE IN MENOPAUSAL WOMEN. *PRZ MENOPAUZALNY*. 2018 DEC;17(4):175-179. DOI: 10.5114/pm.2018.81742. EPUB 2018 DEC 31. PMID: 30766465; PMCID: PMC6372850.
- 6. SORIGUER F, MORCILLO S, HERNANDO V, ET AL. TYPE 2 DIABETES MELLITUS AND OTHER CARDIOVASCULAR RISK FACTORS ARE NO MORE COMMON DURING MENOPAUSE: LONGITUDINAL STUDY. *MENOPAUSE*. 2009;16(4):817–821. [DOI] [PubMed] [Google Scholar]
- 7. MISHRA GD, CARRIGAN G, BROWN WJ, BARNETT AG, DOBSON AJ. SHORT-TERM WEIGHT CHANGE AND THE INCIDENCE OF DIABETES IN MIDLIFE: RESULTS FROM THE AUSTRALIAN LONGITUDINAL STUDY ON WOMEN'S HEALTH. *DIABETES CARE*. 2007;30(6):1418–1424. [DOI] [PubMed] [Google Scholar]
- 8. KIM C, EDELSTEIN SL, CRANDALL JP, ET AL. MENOPAUSE AND RISK OF DIABETES IN THE DIABETES PREVENTION PROGRAM. *MENOPAUSE*. 2011;18(8):857–868. [DOI] [PMC FREE ARTICLE] [PubMed] [Google Scholar]
- 9. BRUNS CM, KEMNITZ JW. SEX HORMONES, INSULIN SENSITIVITY, AND DIABETES MELLITUS. *ILAR J*. 2004;45(2):160–169. [DOI] [PubMed] [Google Scholar]
- 10. WESTPHAL SA. OBESITY, ABDOMINAL OBESITY, AND INSULIN RESISTANCE. *CLIN CORNERSTONE*. 2008;9(1):23–31.
- 11. MAUVAIS-JARVIS F, MANSON JAE, STEVENSON JC, FONSECA VA. MENOPAUSAL HORMONE THERAPY AND TYPE 2 DIABETES PREVENTION: EVIDENCE, MECHANISMS, AND CLINICAL IMPLICATIONS. *ENDOCR REV*. 2017;38(3):173–188. [DOI] [PMC FREE ARTICLE] [PubMed] [Google Scholar]
- 12. KANAYA AM, HERRINGTON D, VITTINGHOFF E, ET AL. GLYCEMIC EFFECTS OF POSTMENOPAUSAL HORMONE THERAPY: THE HEART AND ESTROGEN/PROGESTIN REPLACEMENT STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. *ANN INTERN MED*. 2003;138(1):1–9. [DOI] [PubMed] [Google Scholar]
- 13. MARGOLIS KL, BONDS DE, RODABOUGH RJ, ET AL. EFFECT OF OESTROGEN PLUS PROGESTIN ON THE INCIDENCE OF DIABETES IN POSTMENOPAUSAL WOMEN: RESULTS FROM THE WOMEN'S HEALTH INITIATIVE HORMONE TRIAL. *DIABETOLOGIA*. 2004;47(7):1175–1187. [DOI] [PubMed] [Google Scholar]
- 14. EL KHOUDARY SR, GREENDALE G, CRAWFORD SL, ET AL. THE MENOPAUSE TRANSITION AND WOMEN'S HEALTH AT MIDLIFE: A PROGRESS REPORT FROM THE STUDY OF WOMEN'S HEALTH ACROSS THE NATION (SWAN). *MENOPAUSE*. 2019;26(10):1213–1227.
- 15. KRAVITZ HM, JOFFE H. SLEEP DURING THE PERIMENOPAUSE: A SWAN STORY. *OBSTET GYNECOL CLIN NORTH AM*. 2011;38(3):567–586.



THANK YOU

WHITNEY CROWE MD, MSCP

WHITNEY.CROWE@INTEGRISHEALTH.ORG